Cell killing of melanoma B16 in vivo by hyperthermia and cytotoxins

International Journal of Hyperthermia

Volumn 18, Issue 1, 2002, Pages 62-71

  Stojkovic, R ^a   Radacic, M ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Cytotoxins; Local hyperthermia; Melanoma B16; Mice; Therapy

Indexed keywords

1 (2 CHLOROETHYL) 1 NITROSO 3 (METHYLENECARBOXAMIDO)UREA; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CELL KILLING; CONTROLLED STUDY; DRUG EFFECT; DRUG SYNTHESIS; HIGH TEMPERATURE PROCEDURES; HYPERTHERMIC THERAPY; IN VIVO STUDY; MALE; MELANOMA B16; MOUSE; NONHUMAN; TRANSPLANTABLE SOLID TUMORS;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTOTOXINS; DACARBAZINE; HYPERTHERMIA, INDUCED; MALE; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NITROSOUREA COMPOUNDS; SKIN NEOPLASMS;

EID: 0036150123     PISSN: 02656736     EISSN: None     Source Type: Journal    
DOI: 10.1080/02656730110088373     Document Type: Article

References (72)

1. Interaction of hyperthermia and chemotherapy in animals: A review
2. Selective damage to cancer cells by protein denaturation
3. Enhancement of mammalian cell sensitivity to hyperthermia by pH alteration
4. Influence of extracellular pH on the viability and morphology of tumour cells exposed to hyperthermia
5. The influence of hypoxia and acidity on the hyperthermic response of malignant cells in vitro
6. Effect of pH on hyperthermic cell survival
7. Hopoxic and pH modification on hyperthermic lethality
8. Blood flow
9. Cross-linking of complementary strands of DNA in mammalian cells by antitumour platinum compounds
10. Possible mechanisms for the antitumor activity of platinum coordination complexes
11. DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum (II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity
12. DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloro-platinum (II) and L-phenylalanine mustard
13. Cis-diamminedichloro-platinum (II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: Quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diammine-dichloroplatinum (II)
14. The major adduct of the antitumor drug cisdiamminedichloroplatinum (II) with DNA bends the duplex by approximately equal to 40 degrees toward the major groove
15. Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model
16. Combined hyperthermia and cis=diamminedichloroplatinum in BD IX rats with transplanted BT4A tumours
17. Acute systemic toxicity of combined cis-diamminedichloroplatinum and hyperthermia in the rat
18. Effect of cis-diamminedichloroplatinum (II) combined with whole body hyperthermia on renal injury
19. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats
20. Cisplatin and hyperthermia treatment of C3H mammary carcinoma in vivo
21. Pharmacologic studies of the antitumor agent 5-(dimethyl-triazeno)imidazole-4-carboxamide
22. Methylation of nucleic acids and urinary excretion of 14 C-labeled 7-methylguanine by rats and man after administration of 4(5)-(3,3-dimethyl-1-triazeno)-imidazole 5(4)-carboxomide
23. Pharmacologic principles
24. Thermochemotherapy for melanoma metastases in liver
25. Predictability of response to clinical thermochemotherapy by the clonogenic assay
26. Clinical thermochemotherapy. A controlled trial in advanced cancer patients
27. Hyperthermic antiblastic perfusion with DTIC in stage IIIA-IIIAB melanoma of the extremities
28. Seven years experience with hyperthermic perfusions in extracorporeal circulation for melanoma of the extremities
29. Clinical pharmacokinetics of commonly used anticancer drugs: A review
30. Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells
31. The pharmacology of anticancer drugs
32. Hyperthermia and drugs. Recent results
33. The synergistic effect of hyperthermia and chemotherapy on murine transitional cell carcinoma
34. Synergism between hyperthermia and cyclophosphamide in vivo: The effect of dose fractionation
35. The current and potential role of hyperthermia in radiotherapy: A review
36. Change of temperature in mouse tumour tissue immersed in a water bath at 44 degrees C
37. Thermal enhancement of DNA damage in mammalian cells treated with cis-diammine-dichloroplatinum (II)
38. Enhancement of cis-platinum (II) diaminedichloride cytotoxicity by hyperthermia
39. Temperature dependence of adriamycin, cis-diammine-dichloroplatinum, bleomycin, and 1,3-bis (2-chloroethyl) - 1-Nitrosourea cytotoxicity in vitro
40. Termoterapija i fototerapija tumora
41. Results of cisplatin hyperthermic isolation perfusion for stage IIIA and IIIAB extremity melanoma
42. Effects of intralesional versus ip administration of cisplatin on squamous cell carcinoma of mice
43. O-(beta-Hydroxyethyl)-rutoside-mediated protection of renal injury associated with cis-diamminedichloroplatinum (II)/hyperthermia treatment
44. Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment
45. An experimental model for the study of thermo chemotherapy in vivo
46. Responses of tumour cell lines implanted onto the chorioallantoic membrane of chick emrbyo to anticancer agents in combination with hyperthermia
47. Thermochemotherapy in vivo of a C3H mouse mammary carcinoma: Single fraction heat and drug treatment
48. Fractionated thermochemotherapy in vivo of a C3H mouse mammary carcinoma
49. Local hyperthermia enhances cyclophosphamide, ifosfamide and cis-diammine-dichloroplatinum cytotoxicity on human-derived breast carcinoma and sarcoma xenografts in nude mice
50. Reduction of tumor burden in a murine osteosarcoma following hyperthermia combined with cyclophosphamide
51. Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II study
52. Fotemustine: An overview of its clinical activity in disseminated malignant melanoma: A review
53. Fotemustine and DTIC combination in patients with disseminated malignant melanoma
54. Hyperthermia and drugs
55. Hyperthermia
56. Thermochemotherapy for malignant melanoma: Combination therapy of ACNU and hyperthermia in mice
57. Cisplatin
58. Dacarbazine
59. Cyclophosphamide
60. Chemotherapy of neoplastic diseases. Antineoplastic agents
61. Effect of local hyperthermia on blood flow and microenvironment: A review
62. Pharmacokinetics and temperature: A review
63. Hyperthermic potentiation of cis-diamminedichloroplatinum (II) cytotoxicity in Chinese hamster ovary cells resistant to the drug
64. The effect of hyperthermia on human colon cancer xenografts in nude mice
65. Tumour microcirculation as a target for hyperthermia: A review
66. Interaction of drugs and hyperthermia in vitro and in vivo
67. Time dependency in plasmatic protein binding of cisplatin
68. Protein binding of five platinum compounds. Comparison of two ultrafiltration systems
69. Glutathione metabolism as a determinant of therapeutic efficacy: A review
70. Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells
71. Cellular glutathione, thermal sensitivity, and thermotolerance in Chinese hamster fibroblasts and their heat-resistant variants